
Indoco Remedies (INDOCO) | Stock Overview & Key Data
Indoco Remedies Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹530.25 on August 9, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Dividend Information
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Indoco Remedies INDOCO | 26.28B Small-cap | 0.37% | -10.63% | 13.20% | 15.94% | -14.18% | -12.79% | -18.88% | 15.19% |
Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 2.69% | -2.45% | -3.91% | -3.48% | -13.15% | -5.82% | 82.10% | 208.33% |
Divi's Laboratories DIVISLAB | 1.63T Large-cap | 0.02% | -9.53% | -1.34% | 4.94% | 0.98% | 32.34% | 65.91% | 88.85% |
Sun Pharma Advanced SPARC | 45.51B Small-cap | -3.92% | -13.01% | -6.93% | -0.76% | -30.12% | -34.25% | -41.92% | -22.97% |
Aarti Drugs AARTIDRUGS | 44.42B Small-cap | -3.86% | 1.23% | 5.23% | 18.26% | 6.84% | -2.04% | 8.97% | -37.88% |
Sequent Scientific SEQUENT | 43.92B Small-cap | 0.45% | -5.27% | 0.82% | 19.96% | -4.81% | 22.66% | 59.79% | 34.23% |
Ownership & Short Interest
Indoco Remedies Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Indoco Remedies would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is INDOCO's 52-week high and low?
- In the last 52 weeks, Indoco Remedies reached a high of ₹387.55 (on September 6, 2024) and a low of ₹190.00 (on February 28, 2025).
- What is the market cap and P/E ratio for INDOCO?
- Curious about Indoco Remedies's size and valuation? Its market capitalization stands at 26.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is 101.34, and the forward P/E (looking ahead) is 21.23.
- Does INDOCO pay dividends? If so, what's the yield?
- Yes, Indoco Remedies is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.53%, and the company has paid an average of ₹1.75 per share annually over the past 3 years.
- Who are Indoco Remedies's main competitors or similar companies to consider before investing?
When looking at Indoco Remedies, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -5.82% 82.10% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 32.34% 65.91% Sun Pharma Advanced
SPARC45.51B Healthcare Drug Manufacturers - Specialty & Generic -34.25% -41.92% Aarti Drugs
AARTIDRUGS44.42B Healthcare Drug Manufacturers - Specialty & Generic -2.04% 8.97% Sequent Scientific
SEQUENT43.92B Healthcare Drug Manufacturers - Specialty & Generic 22.66% 59.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Indoco Remedies Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Indoco Remedies's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -7.24%, the Debt to Equity ratio from the most recent quarter is 97.56, and its Gross Profit Margin stands at 68.54%.
- What is the recent revenue and earnings growth for INDOCO?
- Looking at Indoco Remedies's growth, its revenue over the trailing twelve months (TTM) was INR17B. Compared to the same quarter last year (YoY), quarterly revenue grew by 1.50%, and quarterly earnings saw a YoY growth of 1.13%.
- How much of INDOCO stock is held by insiders and institutions?
- Wondering who owns Indoco Remedies stock? Company insiders (like executives and directors) hold about 61.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 19.22%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.